A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Zanubrutinib (Primary) ; Clarithromycin; Diltiazem; Fluconazole; Voriconazole
- Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors BeiGene
- 17 Feb 2023 Additional primary endpoints added.
- 01 Feb 2023 Results assessing pharmacokinetics, efficacy, and safety of zanubrutinib when coadministered with moderate or strong CYP3A inhibitors in 26 patients with relapsed or refractory B-cell malignancies published in the Leukemia and Lymphoma
- 18 Jul 2022 Status changed from active, no longer recruiting to completed.